← Eichor
Study identifier: NCT05304221 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Prospective Cluster-Randomized, Controlled Crossover Trial to Validate an Electronic "Resistance Calculator"

Condition: Sepsis  ·  Sponsor: Dror MarChaim, MD

PhaseN/A
Planned participants1500
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Primary objective: \- Our aim is to validate the "Shamir Resistance Calculator" in a prospective crossover trial, in order to shorten the time to initiation of appropriate antimicrobials among hospitalized septic patients. Secondary objectives: \- To evaluate the impact of using the "Shamir Resistance Calculator" with regards to: * new acquisitions of multi-drug resistant organisms (MDRO) * the empiric usage of broad-spectrum agents (e.g., carbapenems, vancomycin) * acute Clostridiodes difficile infections * In-hospital mortality.

This description comes directly from the study's public registry record.

Talk to the study team

Dror Marchaim, M.D  ·  +972-8-9778146  ·  drormarchaim@shamir.gov.il

Ron Finkenberg  ·  +97289778248  ·  ronfin@shamir.gov.il

Always discuss trial participation with your own doctor first.

Locations (2)

Shamir Medical Center (Assaf Harofeh)Be’er Ya‘aqov, IsraelRecruiting
Hadassah Medical OrganizationJerusalem, IsraelRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05304221